Compare TFII & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TFII | PRAX |
|---|---|---|
| Founded | 1957 | 2015 |
| Country | Canada | United States |
| Employees | 24900 | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 9.6B |
| IPO Year | 2012 | 2020 |
| Metric | TFII | PRAX |
|---|---|---|
| Price | $103.34 | $304.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 15 |
| Target Price | $126.42 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 384.3K | 325.2K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 1.64% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.11 | N/A |
| Revenue Next Year | $5.23 | $6,395.88 |
| P/E Ratio | $31.26 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $72.02 | $26.70 |
| 52 Week High | $127.44 | $354.87 |
| Indicator | TFII | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 32.41 | 42.73 |
| Support Level | $84.73 | $290.36 |
| Resistance Level | $111.99 | $322.32 |
| Average True Range (ATR) | 4.43 | 16.79 |
| MACD | -1.69 | -4.88 |
| Stochastic Oscillator | 0.06 | 25.06 |
TFI International Inc is involved in the provision of transportation and logistics services across the United States, Canada, and Mexico. The company's reportable segments are; Less-Than-Truckload, which derives maximum revenue, Truckload, and Logistics. The Less-Than-Truckload segment engages in pickup, consolidation, transport, and delivery of smaller loads; the Truckload segment deals with full loads carried directly from the customer to the destination using a closed van or specialized equipment to meet customer's specific needs; and the Logistics segment provides asset-light logistics services, including brokerage, freight forwarding, and transportation management, as well as small package parcel delivery. Geographically, the company generates maximum revenue from the United States.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.